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Background: Conventional anti-HIV drug regimens targeting viral enzymes are plagued by the emergence of drug
resistance. There is interest in targeting HIV-dependency factors (HDFs), host proteins that the virus requires for
replication, as drugs targeting their function may prove protective. Reporter cell lines provide a rapid and
convenient method of identifying putative HDFs, but this approach may lead to misleading results and a failure to
detect subtle detrimental effects on cells that result from HDF suppression. Thus, alternative methods for HDF
validation are required. Cellular Tat-SF1 has long been ascribed a cofactor role in Tat-dependent transactivation of
viral transcription elongation. Here we employ sustained RNAi-mediated suppression of Tat-SF1 to validate its
requirement for HIV-1 replication in a CD4+ T cell-derived line and its potential as a therapeutic target.
Results: shRNA-mediated suppression of Tat-SF1 reduced HIV-1 replication and infectious particle production from
TZM-bl reporter cells. This effect was not a result of increased apoptosis, loss of cell viability or an immune
response. To validate its requirement for HIV-1 replication in a more relevant cell line, CD4+ SupT1 cell populations
were generated that stably expressed shRNAs. HIV-1 replication was significantly reduced for two weeks (~65%) in
cells with depleted Tat-SF1, although the inhibition of viral replication was moderate when compared to SupT1
cells expressing a shRNA targeting the integration cofactor LEDGF/p75. Tat-SF1 suppression was attenuated over
time, resulting from decreased shRNA guide strand expression, suggesting that there is a selective pressure to
restore Tat-SF1 levels.
Conclusions: This study validates Tat-SF1 as an HDF in CD4+ T cell-derived SupT1 cells. However, our findings also
suggest that Tat-SF1 is not a critical cofactor required for virus replication and its suppression may affect cell
growth. Therefore, this study demonstrates the importance of examining HIV-1 replication kinetics and cytotoxicity
in cells with sustained HDF suppression to validate their therapeutic potential as targets.Background
Current anti-HIV drug regimens target several viral
enzymes simultaneously, with the aim of preventing the
emergence of drug resistance. However, efficacy of these
drugs is limited by the problems of emergence of drug
resistance that results from viral diversity and mutability.
Host factors required by the virus for replication, so-
called HIV-dependency factors (HDFs), represent at-
tractive therapeutic targets since their coding sequences* Correspondence: Marc.Weinberg@wits.ac.za
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reproduction in any medium, provided the orremain constant relative to the sequence variability of
viral targets within a patient and across the pandemic.
Support for the notion that HDFs may be suitable
therapeutic targets comes from a genome association
study showing that single nucleotide polymorphisms in
ZNRD1 are associated with slowed disease progression
[1], and that a naturally occurring deletion in the CCR5
gene renders individuals resistant to an R5-tropic virus
infection without associated physiological problems
[2,3]. There have been several clinical trials showing the
positive impact CCR5 deletion from CD4+ T cells has
on T cell longevity, viral suppression and patient health
(reviewed in [4]). This was most emphatically demon-
strated by the apparent cure of the ‘Berlin patient’ [5-7].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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modulate HIV infection since drugs inhibiting their
function may prove protective.
A number of reporter cell lines have been developed
as convenient laboratory tools for the quantification of
HIV replication. When coupled with RNA interference
(RNAi)-mediated gene silencing, these models provide a
rapid method for the identification of putative HDFs.
This approach has been employed in genome-wide stud-
ies [8,9]. However, most putative HDFs identified by such
approaches have yet to be validated in cells that are nat-
urally infected by HIV. This is necessary as reporter cell
lines may be misleading with respect to HDF importance,
as exemplified in a study where only half of putative
HDFs were validated as such in a T cell-derived line [10].
HIV-1 Tat-specific factor 1 (Tat-SF1) [NCBI RefSeq_
peptide: NP_055315] has long been a candidate HDF
since its identification as a cofactor for Tat-dependent
transactivation of viral transcription elongation [11-14].
Tat-SF1 is an RNA-binding protein [12] that functions
as a transcription elongation and splicing factor of cellu-
lar transcripts [15-17]. Most of the previous work
on Tat-SF1 has focused on in vitro immunodepletion
experiments of nuclear extracts. Other studies have
demonstrated that RNAi-mediated suppression of Tat-
SF1 inhibited HIV-1 replication in the HeLa-derived
TZM-bl reporter cell line [8,18], mediated by a disrup-
tion to splicing of viral transcripts [18]. However, it was
unknown whether this protein functions as an HDF in
cells that are a natural target of HIV and, if so, whether
the long-term impact of suppressing Tat-SF1 adversely
affects these cells.
In this study we examined the impact of Tat-SF1 sup-
pression, mediated by anti-Tat-SF1 short hairpin RNAs
(shRNAs), in both TZM-bl reporter cells and CD4+
T cell-derived SupT1 cell lines. Inhibition of Tat-SF1 ex-
pression resulted in a significant inhibition of HIV-1 repli-
cation, although this was less pronounced than when
suppressing the known lentiviral integration cofactor
LEDGF/p75 [19,20]. In addition, Tat-SF1 suppression was
attenuated during serial passage of transduced SupT1 cell
lines, suggesting that Tat-SF1 suppression may confer a
growth disadvantage to cells and therefore preclude its
utility as a therapeutic target. The approach used here
demonstrates that thorough analysis is required for HDF
validation and detection of subtle changes to cell physi-
ology that may result from HDF inhibition.
Results
RNAi-mediated suppression of Tat-SF1 without
cytotoxicity
RNAi effectors, such as shRNAs, may be exploited to
validate roles of HDFs. To suppress expression of en-
dogenous Tat-SF1, which is encoded by the HTATSF1gene, three U6 RNA Polymerase (Pol) III shRNA expres-
sion cassettes, shhtatsf1-a, shhtatsf1-b and shhtatsf1-c,
were generated (Additional file 1A). The shRNA loop
sequences were derived from micro RNA- (miR-) 31.
Through the introduction of mismatches in the anti-
guide strand, G:U wobbles were created to enhance the
thermodynamic asymmetry of the shRNA stems and fa-
cilitate intended mature guide strand bias [21-23].
Initial assessment of the ability of shRNAs to knock-
down their cognate target sequences was made using a
dual luciferase reporter assay. The three Tat-SF1 mRNA
(htatsf1) target sites were inserted downstream of the
Renilla luciferase ORF within a psiCheck dual-luciferase
plasmid. Ratios of Renilla to constitutively expressed fire-
fly luciferase activities were used to assess efficiency of
shRNA-mediated target knockdown. All htatsf1-targeted
shRNAs significantly reduced Renilla/firefly luciferase
activity ratios compared to controls ie cells receiving
the U6 plasmid, a construct with shRNA expression
targeting hepatitis B virus X protein (shHBVx-5) [24]
or the psiCheck target construct only (>90% knock-
down; Figure 1A). Greatest knockdown was observed
with shhtatsf1-a, which effectively inhibited expression
of the endogenous mRNA target in TZM-bl cells, as
determined by quantitative reverse transcription PCR
(qRT-PCR) (~60% knockdown; Figure 1B). Western
blot analysis demonstrated that shhtatsf1-a expression
also mediated a significant reduction in Tat-SF1 (4% of
shHBVx-5 control; Figure 1C). Small RNA Northern
blot detected the ~21 nt shhtatsf1-a guide strand
(Figure 1D), confirming that the exogenous shRNA was
processed as intended and that the observed suppres-
sion of Tat-SF1 expression was mediated by an RNAi
mechanism.
Ass essing the extent of toxic effects on introduction
of shRNAs targeting Tat-SF1 expression is important,
both in terms of validating this protein as a therapeutic
target and in analysing the effect that the suppression of
Tat-SF1 has on HIV-1 replication. Cytotoxicity may re-
sult from direct knockdown of Tat-SF1, non-specific si-
lencing of cellular genes, or from induction of an innate
immune response. The latter is likely to be triggered by
the presence of exogenous double-stranded RNAs within
the cell [25]. No increase in apoptosis was observed in
TZM-bl cells 72 h post-shhtatsf1-a transfection, in con-
trast to cells treated with a high dose of the histone dea-
cetylase inhibitor, trichostatin-A (Figure 1E). Neither
was there altered mitochondrial dehydrogenase activity
on shhtatsf1-a expression, compared with TZM-bl cells
transfected with the U6 plasmid (Additional file 2). In-
duction of an innate immune response, monitored by
quantification of interferon-β mRNA (ifnb1) expression,
was also not evident (Figure 1F). Collectively these
















































































































































































































Figure 1 shRNAs suppress Tat-SF1 expression without
cytotoxicity. 1A. Dual luciferase activities were assessed in HeLa cell
lysates 48 h post-transfection with shRNA expression cassettes and
psiCheck reporter constructs, in triplicate. Target Renilla luciferase
levels are given relative to firefly luciferase and normalised to a
mock construct with no shRNA expression (U6). shHBVx-5, which
targets a sequence in HBV X protein, was included as a negative
control. 1B. Total RNA was analysed by qRT-PCR 48 h post-
transfection of TZM-bl cells with shRNA expression plasmids, or the
U6 mock construct, in triplicate. Tat-SF1 mRNA (htatsf1) levels are
given relative to β-actin mRNA (actb) normalised to the U6 control.
1C. TZM-bl cell lysates were subject to PAGE and Western blot 72 h
post-transfection. Tat-SF1 expression is given relative to β-actin and
normalised to the shHBVx-5 control. 1D. Total TZM-bl RNA isolated
48 h post-transfection was subject to small RNA PAGE and Northern
blot. shRNA guide strand expression is given relative to U6 small
nuclear RNA and normalised to the U6 control. 1E. TZM-bl cells were
stained with Annexin V-conjugated FITC 72 h post-transfection, in
duplicate. As a positive control for apoptosis induction, additional
cells were treated with 500 nM trichostatin-A (TSA) 16 h pre-stain.
Two images were acquired per sample and FITC levels quantified by
ImageJ. 1F. Levels of interferon-β mRNA (ifnb1) relative to β-actin
mRNA (actb) were determined by qRT-PCR on total cellular RNA
extracted 48 h post-transfection, in triplicate. Poly(I:C) dsRNA was
used as a positive control. Data are expressed as the mean ± SEM. *,
p <0.05, one-way ANOVA with Dunnett post-tests relative to mock
construct, U6.
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Tat-SF1 expression without inducing apoptosis or an
interferon response in TZM-bl cells.
Suppression of Tat-SF1 inhibits HIV-1 replication in
reporter cells
The effects of Tat-SF1 silencing on HIV-1 replication
were initially assessed in TZM-bl cells. HeLa-derived
TZM-bl cells may be infected with HIV-1 to a similar
extent to human peripheral blood mononuclear cells
(PBMCs) because they express transgenic HIV receptor
CD4 and coreceptor CCR5 [26-28]. Furthermore, TZM-
bl cells permit relatively simple assessment of HIV-1
replication as they contain an integrated Tat-dependent
luciferase reporter [26-28].
HIV-1 replication was quantified both by measure-
ment of capsid protein p24 levels in culture supernatant
and Tat-induced reporter gene activity (Figure 2A). Cells
were transfected with the shhtatsf1-a expression con-
struct, or controls, and infected 48 h later with virus
derived from the HIV-1 subtype B molecular clone
p81A-4 (HIV-1p81A-4) [29,30]. Tat-induced luciferase ac-
tivity in cells with suppressed Tat-SF1 expression was
~20% of controls at 48 h after infection (Figure 2B). This
effect was similar to that observed in cells expressing
shTAT and shLTR-U5, previously developed shRNA ex-
pression cassettes that directly target sequences within
the Tat open reading frame (ORF) and U5 region of the
viral leader transcripts, respectively [31,32]. Tat-SF1 sup-
pression also reduced infectious particle production by
~70% (Figure 2C). Collectively these results confirm previ-
ous reports that Tat-SF1 functions as an HDF in TZM-bl
cells [8,18]. Given the limitations associated with transient
host factor suppression for HDF validation, and the poten-
tial bias of reporter output, the impact of sustained Tat-
SF1 suppression on HIV-1 replication kinetics over a time
course was investigated.
Stable expression of htatsf1-targeting shRNAs in SupT1
cells inhibits HIV-1 replication
The impact of sustained Tat-SF1 suppression on HIV-1
replication kinetics was assessed in CD4+ T cell-derived
SupT1 cells [33], a model that more closely simulates
natural HIV-1 infection than TZM-bl cells. An add-
itional control shRNA was used, shpsip1-a, targeting the
known HIV-1 cofactor LEDGF/p75 [20], which is
encoded by the PSIP1 gene. U6 RNA Pol III shRNA ex-
pression cassettes were incorporated into second-
generation lentiviral vectors that also included a GFP
reporter cassette. The dual luciferase reporter assay con-
firmed that the shRNAs remained capable of target si-
lencing within the context of the lentivector (Additional
file 3A). Recombinant lentiviruses were then generated
and used to transduce SupT1 cells at a multiplicity of
AB C
Figure 2 Tat-SF1 suppression inhibits HIV-1 infectious particle production from TZM-bl cells. 2A. Schematic of the HIV-1 infection
protocol. 2B. TZM-bl cell lysates were analysed for luciferase activity 72 h post-transfection and 48 h post-infection with HIV-1p81A-4 at a TCID50 of
1000/ml, in triplicate. shLTR-U5 and shTAT, which target viral RNAs, were included as positive controls. 2C. Untransfected TZM-bl cell lysates were
analysed for luciferase activity 48 h post-incubation with culture supernatant isolated from shRNA-expressing TZM-bl cells. Luciferase activity is
given relative to culture supernatant p24 concentration, determined by ELISA. Data are expressed as the mean ± SEM. *, p <0.05, one-way
ANOVA with Dunnett post-tests relative to mock construct, U6.
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sorting (FACS), a population of transduced SupT1 cells
was propagated (Additional file 3B and C).
SupT1 cells with stable shRNA expression were
infected with HIVp81A-4. HIV-1 p24 concentrations in
culture supernatant were measured regularly during a
period of 17 days to assess HIV-1 replication kinetics
(Figure 3A). The concentration of p24 rose to ~5 μg/ml
on day 14 in the culture supernatant of control cells
with no shRNA, or shHBVx-5, expression. No p24 meas-
urement was made in these control cells on day 17 as a
result of cell death from the high levels of virus replica-
tion. In contrast, p24 levels in culture supernatant of
cells expressing shpsip1-a were only detected on day 4,
and never reached more than 0.1 μg/ml during the time
course, in accordance with the importance of LEDGF/
p75 in HIV-1 replication [20]. Culture supernatant of
cells with shhtatsf1-a expression exhibited p24 levels of
~2 μg/ml on day 14 (Figure 3A), a reduction of ~65%
compared with the U6 mock, which was similar to that
observed with shLTR-U5 expression (Figure 3B). These
data show that sustained Tat-SF1 suppression inhibits
HIV-1 subtype B replication in a T cell-derived line, al-
beit to a lesser extent than silencing of LEDGF/p75.Tat-SF1 expression increases following serial passage of
shhtatsf1-a-expressing SupT1 cells
Close inspection of HIVp81A-4 replication kinetics reveals
that on day 14, p24 levels in shhtatfs1-a-‐expressing
SupT1 cells, relative to the U6 control, were increasedcompared with day 10 (~95% versus ~65% knockdown;
Figure 3B). In contrast, the suppression of p24 levels in
shLTR-U5-‐expressing cells was maintained at ~75%.
The apparent attenuation of HIV-1 replication inhibition
may result from adaptation of the virus to another cofac-
tor, or may be a result of increased Tat-SF1 expression.
However, cofactor adaptation is unlikely considering the
duration of the assay. To determine whether there was
increasing Tat-SF1 expression over the time course,
SupT1 cell lines were raised and cultured for periods
equivalent to the HIVp81A-4 replication assay. The level of
htatsf1 mRNA was suppressed throughout, compared to
the U6 control, although htatsf1 mRNA concentration
increased significantly from day 10 (~49%) to day 20
(~70%; Figure 4A). These results were corroborated by
Western blot analysis of Tat-SF1 expression (Figure 4B).
In contrast, the degree of suppression of psip1 mRNA
was sustained in the shpsip1-a-expressing cell line
throughout the time course (Figure 4A), demonstrating
that the increase in shRNA target expression was specific
to the shhtatsf1-a-expressing SupT1 cell line.
Several mechanisms, which are not mutually exclusive,
may account for the observed increase in Tat-SF1 ex-
pression during serial passage of SupT1 cells expressing
shhtatsf1-a. These are: (1) increased HTATSF1 transcrip-
tion; (2) reduced shhtatsf1-a expression; and, (3) positive
selection for untransduced cells in the population where
there is no Tat-SF1 suppression. Nuclear run-on analysis
revealed no alteration in HTATSF1 transcription rates,
relative to transcription of ACTB, at day 20 compared












































Figure 3 Sustained Tat-SF1 suppression inhibits HIV-1
replication in CD4+ T cell-derived SupT1 cells. SupT1 cell lines,
with stable shRNA expression generated by lentiviral transduction,
were infected with HIV-1p81A-4 at a TCID50 of 50/ml, in triplicate. 3A.
Levels of p24 in culture supernatant were determined by ELISA 0, 2,
4, 7, 10, 14 and 17 days post-infection. Crosses indicate discontinued
p24 measurement as a result of cell death. 3B. p24 levels in SupT1
cells expressing either shLTR-U5 or shhtatsf1-a, relative to the U6
mock, at days 10 and 14 post-infection. Data are expressed as the
mean ± SEM.
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sion of the shhtatsf1-a-derived guide strand was ~30% at
day 20 of that detected on day 0 (Figure 4D), whereas
the reduction in shpsip1-a-derived guide strand was less
pronounced (~87% at day 20; Additional file 4). Flow
cytometry on SupT1 cell lines over the time course
showed that the GFP+ cells slightly diminished in the
population transduced with shhtatsf1-a-expressing lenti-
virus, in contrast to SupT1 populations with no shRNA,
or shpsip1-a, expression (Figure 4E). The size of the
population transduced with shhtatsf1-a-expressing len-
tivirus was less than controls, as indicated by quanti-
fication of extracted DNA, although not significant
(Figure 4F). Collectively, these data demonstrate that the
inhibition of HIV-1 replication on Tat-SF1 suppression
is attenuated over time as a result of an increase in Tat-SF1 expression. Such an increase is predominantly a re-
sult of a decrease in shhtatsf1-a guide strand expression.
Discussion
Here we demonstrate that suppression of Tat-SF1 inhi-
bits HIV-1 replication in both TZM-bl reporter cells and
CD4+ T cell-derived SupT1 cells. Tat-SF1 has previously
been shown to function as an HDF in TZM-bl cells [18],
although we further demonstrated that the inhibitory
effect on HIV-1 following RNAi-mediated Tat-SF1 sup-
pression was not a result of cellular toxicity or induction
of an immune response (Figure 1E and F) and includes
inhibition of infectous particle production (Figure 2C).
This study also examined the effect of sustained Tat-
SF1 suppression on HIV-1 replication in T cell-derived
SupT1 cells, a model that more closely mimics natural
HIV-1 cellular targets. This approach had the added
benefit of permitting quantification of HIV-1 replication
kinetics for over two weeks. Tat-SF1 suppression inhib-
ited HIV-1 replication in SupT1 cells throughout the
time course (Figure 3A). Nevertheless, the inhibition of
HIV-1 replication was modest compared with SupT1
cells with sustained suppression of the integration cofac-
tor LEDGF/p75 (Figure 3A), suggesting that Tat-SF1 is a
less critical HIV-1 cofactor than LEDGF/p75. This may
be because Tat-SF1 is involved in increasing the effi-
ciency of viral processes that still occur in its absence.
This is consistent with its proposed function as one of
a set of non-redundant RNA Pol II elongation factors
that act cooperatively to facilitate efficient transcription
elongation [16]. This is also consistent with observations
that Tat-SF1 suppression results in a shift in the ratio of
unspliced to spliced HIV-1 transcripts, but not complete
loss of the spliced class [18]. These effects may be
mediated by Tat-SF1 stabilising the large, multi-protein
transcription elongation and splicing complexes [14],
whilst not being critical for their activities. In contrast,
our results confirm previous reports that LEDGF/p75
is a critical integration cofactor [20], and suggest that
it is a good therapeutic target, as its suppression resul-
ted in almost complete ablation of HIV-1 replication
(Figure 3A). Indeed, there has been considerable pro-
gress in developing LEDGF/p75-HIV-1 integrase inter-
action inhibitors (reviewed in [34]).
Along with the limited inhibition of HIV-1 replication
in SupT1 cells, other observations suggest that Tat-SF1
may not constitute a viable anti-HIV-1 therapeutic tar-
get. Tat-SF1 suppression was attenuated over time in
SupT1 cells (Figure 4A and B) as a result, at least in
part, of decreased shhtatsf1-a guide strand expression
(Figure 4D). This may arise from epigenetic silencing of
the shRNA expression cassette, or untransduced cells
(or transduced cells with low or no shhtatsf1-a expres-



































































































































































































































Figure 4 Attenuation of shRNA-mediated Tat-SF1 suppression over time. Samples were isolated from SupT1 cells with stable shRNA
expression at time points equivalent to those of the HIV-1p81A-4 replication assay. 4A. Total SupT1 RNA was analysed by qRT-PCR, in triplicate.
Target mRNA levels are given relative to β-actin mRNA (actb) normalised to the U6 cell line. Left panel: Tat-SF1 mRNA (htatsf1). Right panel:
LEDGF/p75 mRNA (psip1). 4B. SupT1 cell lysates were subject to PAGE and Western blot. Day 20 samples were prepared in duplicate and
representative blots are shown. Mean Tat-SF1 expression is given relative to β-actin and normalised to the U6 control at each time point.
4C. Nuclei isolated from SupT1 cells were subject to nuclear run-on analysis to quantify htatsf1 transcription, in triplicate. Samples from both
shLTR-U5- and shhtatsf1-a-expressing cells were normalised to those isolated at a time point equivalent to day 0 of the HIV-1p81A-4 replication
assay. 4D. Total SupT1 RNA was subject to small RNA PAGE and Northern blot to assess shhtatsf1-a guide strand expression relative to 5S rRNAs.
4E. Proportion of GFP+ SupT1 cells. SupT1 cell populations were analysed by flow cytometry with 5 × 103 events acquired per sample. 4F.
shRNA-expressing SupT1 cell lines were cultured for 20 days prior to quantification of cellular DNA. Data are expressed as the mean ± SEM. *,
p <0.05, two-way ANOVA with Bonferroni post-tests.
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mechanisms are not mutually exclusive, our data favours
the former as the primary mechanism for the reduction
in guide strand expression, since the decrease in the per-
centage of GFP+ SupT1 cells is less than the reduction
in shhtatsf1-a guide strand expression (Figure 4D and
E). Regardless, when compared to the other SupT1
populations, the reduction in guide strand and percent
of GFP+ cells was specific to the shhtatsf1-a population
(Figure 4D and E, and Additional file 4), implying there
is a selective pressure on cells to restore Tat-SF1 expres-
sion levels. Such a growth disadvantage on Tat-SF1 sup-
pression would account for the small reduction in cell
number within the population after serial passage
(Figure 4F). This was not a significant difference, pos-
sibly because of adaptation to increase Tat-SF1 levels
(Figure 4B).
Reduced Tat-SF1 expression may confer a growth dis-
advantage by disrupting expression of Tat-SF1 transcrip-
tion and splicing targets, which have recently been
shown to include genes involved in the cell cycle and
nucleic acid metabolism [15]. Of course, reduced cell
proliferation is not a desirable side effect, particularly inimmune cells, which may preclude Tat-SF1 inhibition as
an anti-HIV therapeutic strategy. However, it has been
demonstrated that cells with greater resistance to HIV-‐1
replication undergo preferential expansion in vivo [35].
Therefore, any growth disadvantage associated with Tat-
SF1 suppression may be outweighed in vivo by a selective
advantage in the context of an HIV-1 infection. Further
experiments are needed to verify whether this is the case,
but the observations reported here would certainly ex-
clude prophylactic targeting of Tat-SF1. Nonetheless, as
an HDF, Tat-SF1 expression heterogeneity should be con-
sidered a possible HIV-1 susceptibility factor.
More generally, this study highlights the limitations
associated with HDF validation in a reporter cell line.
Although convenient, there may be bias toward host fac-
tors with a more direct influence on reporter gene ex-
pression. In addition, the expression levels of host
factors differ between cell types, which may alter HIV-1
replication kinetics [36], particularly in reporter cell lines
that are not derived from natural targets of HIV-1. Fur-
thermore, measurement of TZM-bl reporter gene activ-
ity requires cell lysis, preventing serial monitoring of
HIV-1 replication and, as such, are most useful for
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overlooking HDFs with long half-lives and not detect
subtle detrimental effects on cell physiology resulting
from HDF suppression. Thus the limitations of bias, cell
type and transient suppression that are associated with
reporter cell lines may cause a distortion in the relative
importance and therapeutic potential of an HDF. This
was observed in this study, where transient suppression-
experiments in TZM-bl cells suggested that Tat-SF1 was
a critical HIV-1 cofactor, in contrast to the findings from
sustained suppression-experiments in SupT1 cells, an
approach which is less subject to distortion from bias
and cell type. Furthermore, this study reveals that Tat-
SF1 suppression may confer a growth disadvantage only
apparent on serial passage of cells. In contrast, previous
reports that LEDGF/p75 comprises a promising thera-
peutic target were confirmed. Overall this study provides
an experimental template for the approach required to
validate HDFs and the therapeutic potential of their tar-
geting, and should be extended to putative HDFs identi-
fied by genome-wide screens.
Conclusions
HDFs represent potential therapeutic targets and, as
such, putative HDFs require validation. Focusing on the
HIV-1 cofactor Tat-SF1, this study highlights the limita-
tions associated with HDF validation in the TZM-bl re-
porter cell line. We demonstrate an alternative approach
for determining the impact that host factor suppression
has on HIV-1 replication and cell physiology, which
employs sustained RNAi-mediated host factor suppres-
sion in a cell line derived from a physiological substrate
of HIV-1. This approach was used to validate Tat-SF1 as
an HDF in CD4+ T cell-derived SupT1 cells: sustained
RNAi-mediated Tat-SF1 suppression inhibits HIV-1 rep-
lication in SupT1 cells. However, the inhibitory effect
was modest compared to cells with sustained suppres-
sion of the integration cofactor LEDGF/p75, suggesting
that Tat-SF1 is not a critical HIV-1 cofactor. Further-
more, Tat-SF1 suppression is attenuated over time, sug-
gesting that reduced Tat-SF1 levels confer a growth
disadvantage to cells. Thus, whilst this study reveals that
Tat-SF1 functions as an HDF in SupT1 cells, further
studies are required to determine whether variants
might modulate HIV-1 infection and its suppression




shRNAs shhtatsf1-a, shhtatsf1-b and shhtatsf1-c were
designed to target htatsf1 transcript [NCBI RefSeq_RNA:
NM_014500.3] at the sequences GCT ACA TAT CAG
GCC AAT TAT, GCG CAT CTA GTT CTA CCG CAAand CTG CAA CTG GAA TGG CGT T, respectively
(Additional file 1). These target sites were selected from
sequences suggested by The RNAi Consortium (www.
broad.mit.edu/genome_bio/trc/rnai.html). All shRNAs
were designed to contain a loop sequence derived from
miR-31. G:U mismatches were incorporated at the 3’ end of
the anti-guide strand of some shRNAs to decrease thermo-
dynamic stability of this end of the hairpin stem and favour
selection of the intended guide strand. RNA Pol III U6
shRNA expression cassettes were generated by a two-step
PCR approach described previously [37]. These were
cloned into pTZ57R/T (Fermentas). Construct sequence
was confirmed by automated cycle sequencing.
Several previously developed constructs were used as
controls in experiments: a mock pTZU6+1 (U6) con-
struct with no shRNA sequence [38]; a shRNA negative
control, shHBVx-5, which targets an irrelevant site in
hepatitis B virus (HBV) X protein [24]; and, two positive
controls, shLTR-U5 and shTAT, which are named after
the location of their target sequences within HIV-1 tran-
scripts and were initially developed based on subtype B
molecular clone HXB2 [GenBank: K03455] [31,32].
shRNA shpsip1-a was adapted from a guide strand pre-
viously shown to inhibit LEDGF/p75 expression [20]
that targets the p75 isoform of psip1 transcript [NCBI
RefSeq_RNA: NM_033222.2] at the sequence GAC AGC
ATG AGG AAG CGA A.
Cell culture and transfections
HeLa-derived TZM-bl cells (NIH AIDS Research and
Reference Reagent Program), which express the HIV re-
ceptor CD4 and coreceptor CCR5 and contain a lucifer-
ase reporter driven by a Tat-inducible LTR promoter
derived from pSG3.1 [GenBank: L02317] [26-28], were
maintained in Dulbecco’s Modified Eagle’s Medium
(DMEM), supplemented with 10% heat-inactivated fetal
calf serum (FCS), at 37°C and 5% CO2. HEK293T, HeLa
and SupT1 cells (NIH AIDS Research and Reference
Reagent Program), the latter a non-Hodgkin’s T cell
lymphoma suspension cell line expressing high levels of
surface CD4 [33], were maintained in the same media.
Transfections were carried out using 1 μl Lipofecta-
mine2000 (Invitrogen) to 1 μg DNA, according to
manufacturer’s instructions. Medium was changed 5 h
post-transfection. Where appropriate, a plasmid with
constitutive eGFP expression (pCI-eGFP) was cotrans-
fected followed by fluorescence microscopy 48 h later to
verify equivalent transfection efficiencies [39].
Dual luciferase reporter assay
To generate psiCheck target plasmids, with all shRNA
target sites for each cellular factor adjacent to one an-
other, complementary oligonucleotides were treated with
polynucleotide kinase (Promega), annealed and cloned
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site was inserted within each annealed dsDNA insert to
facilitate screening. The oligonucleotides used for psi-
Check htatsf1 were: TCG AGA TAT CGC TAC ATA
TCA GGC CAA TTA TGC GCA TCT AGT TCT ACC
GCA AAC TGC AAC TGG AAT GGC GTT GC; and,
CTA GAT GCG CAT AAT TGG CCT GAT ATG TAG
CGA TAT CGG CCG CAA CGC CAT TCC AGT TGC
AGT TTG CGG TAG AA; and, for psiCheck psip1 were:
TCG AGA TAT CAG ACA GCA TGA GGA AGC GAA
GCA GCT ACA GAA GTC AAG ATT GC; and, GGC
CGC AAT CTT GAC TTC TGT AGC TGC TTC GCT
TCC TCA TGC TGT CTG ATA TC. Target constructs
psiCheck HBVx [40] and psiCheck LTR [31] have been
described previously.
HeLa or HEK293T cells were seeded at 5.0 × 104 and
1.2 × 105 cells per well, respectively, in a 24-well culture
plate and transfected 24 h later with 500 ng shRNA
expression construct, 100 ng of psiCheck target reporter
construct and 10 ng pCI-eGFP, in triplicate. Firefly and
Renilla luciferase activities were determined 48 h later
using the Dual Luciferase Reporter Assay System (Pro-
mega) and a Veritas dual-injection luminometer (Turner
Biosystems), according to manufacturer’s instructions.
Renilla: firefly luciferase activity ratios were normalised
to the U6 control mean.
Quantitative RT-PCR of cellular factor mRNAs
TZM-bl cells were seeded at 5.0 × 104 cells per well in a
24-well culture plate and transfected 24 h later with 500 ng
shRNA expression construct and 10 ng pCI-eGFP, in
triplicate. Total TZM-bl cellular RNA was extracted using
TriReagent (Sigma-Aldrich) 48 h later, or from stably
transduced SupT1 cells cultured for periods equivalent
to days 0, 10 and 20 of the HIV-1 replication assay
(see below). Total RNA was subjected to DNase treatment
(Promega) and random-primed reverse-transcription using
the SuperScript III reverse transcriptase (RT) (Invitrogen).
cDNA was analysed for target mRNA expression relative
to β-actin mRNA (actb) transcript NM_01101.2 using
the SensiMix Lite Kit (Quantace) with the following pri-
mers: htatsf1 forward AGTGGGACCTGGACAAAAAGG;
htatsf1 reverse GTT CCG GGG CTT TTT CTT GTG;
psip1 forward GCT GAA CAA AGA CAG CAT GAG
GA; psip1 reverse ATT GCT CTC CCC GTT ATG TTG
TG; actb forward AGG TCA TCA CCA TTG GCA ATG
AG; and, actb reverse TCT TTG CGG ATG TCC ACG
TCA. The qPCR was performed in a Carousel-based Light-
cycler V.2 System (Roche) with the following parameters:
denaturation at 95°C for 10 min, 50 cycles of denaturation
at 95°C, annealing at 60°C and extension at 72°C, each for
10 s. Amplification cycles were followed by melting curve
analysis to verify the specificity of the PCR products. No
RT controls were included for each sample and no cDNAcontrols for each primer set. Target mRNA: actb ratios
were normalised to the mean expression ratio of U6-
transfected samples.
Western blot
TZM-bl cells were seeded at 1.5 × 105 cells per well in a
6-well culture plate and transfected 24 h later with 2 μg
shRNA expression construct and 10 ng pCI-eGFP. Cells
were harvested 72 h post-transfection and lysed with
RIPA buffer. Total protein was quantified using the BCA
Protein Assay Kit (Pierce). A ladder composed of IgG-
binding proteins ranging from 22 to 120 kDa in size and
80 μg of samples were resolved on a 12% polyacrylamide
gel. Protein was transferred to a PVDF membrane (Milli-
pore) and probed with rabbit polyclonal antibodies to
Tat-SF1 (a gift from M. Garcia-Blanco) at 1:100 and
β-actin (GenWay Biotech) at 1:1,000. The latter was
used to quantify loading of samples. HRP-conjugated
donkey anti-rabbit IgG secondary antibody (GenWay
Biotech) was used at a dilution of 1:25,000 and proteins
were detected with SuperSignal West Pico Chemilumin-
escent Substrate (Pierce). Images were acquired with a
G-BOX (Syngene). Levels of target protein are reported
relative to levels of β-actin and normalised to the
shHBVx-5 control.
SupT1 cells were similarly analysed by Western blot,
with the exception that cells were harvested after culture
periods equivalent to days 0 and 20 of the HIV-1 replica-
tion assay (see below). Day 20 samples were prepared in
duplicate. Mean target protein expression relative to
levels of β-actin are reported normalised to the U6 mock
at each time point.Northern blot analysis of shRNA guide strand processing
TZM-bl cells were seeded at 2 × 106 cells in a 60 cm2
culture dish and transfected with 20 μg shRNA expres-
sion plasmid 24 h later. Total cellular RNA was isolated
from TZM-bl cells 48 h post-transfection, or SupT1
cells, using TriReagent (Sigma-Aldrich). Thirty micro-
grams of RNA was resolved on urea denaturing 15%
polyacrylamide gels and blotted onto nylon membranes.
RNA molecular weight markers were run alongside
the cellular RNA. Blots were hybridised to DNA oligo-
nucleotide probes of complementary sequence to
hairpin-derived guide strands and, therefore, of the same
sequence as the shRNA target sequences (see above).
For analysis of TZM-bl RNA, the RNA ladder and
DNA probes were labelled at their 5’ ends with [γ-32P]
ATP and T4 polynucleotide kinase. To quantify loading
of the TZM-bl RNA, an oligonucleotide sequence com-
plementary to U6 small nuclear RNA was used of the
following sequence: TAG TAT ATG TGC TGC CGA
AGC GAG CA. Following hybridisation, blots were
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phosphorimager (Fujifilm), stripped and reprobed.
For SupT1 RNA analysis, levels of 5S rRNAs on the
ethidium bromide-stained polyacrylamide gel verified
equal loading of the samples. The RNA ladder and DNA
probes were labelled at their 3’ ends with the DIG Oligo-
nucleotide 3’-end Labelling Kit according to manufac-
turer’s instructions (Roche). Following hybridisation,
chemiluminescence detection of bound probes was
enabled by incubation of the membranes with alkaline
phosphatase-conjugated anti-DIG antibody, incubation
with CDP-Star (Roche) and image acquisition with a
G-BOX (Syngene).
Apoptosis quantification
TZM-bl cells were seeded at 3 × 104 cells per well on
CELLocate microgrid coverslips (Eppendorf ) in a 24-
well culture plate. Cells were transfected with 500 ng
shRNA expression constructs 24 h later, in duplicate.
Another subset of cells was treated with 500 nM
trichostatin-A 80 h post-seeding as a positive control.
Seventy-two hours post-transfection, or 16 h post-
trichostatin-A treatment, apoptosis was quantified using
the TACS Annexin V-FITC Apoptosis Detection Kit
(R&D Systems). Fluorescence images were acquired for
two fields of view per well on an Axiovert 100 M micro-
scope with image capture by AxioVision 2.0.5 software
(Carl Zeiss Microimaging). Fluorescence was quantified
using ImageJ 1.40 g (developed by W. Rasband, NIH)
and reported normalised to the U6 mock.
MTT assay for cell viability
TZM-bl cells were seeded at 1 × 104 cells per well in a 96-
well culture plate. Cells were either transfected with 100
ng shRNA expression construct, or treated with 10, 100 or
500 nM trichostatin-A, 24 h later, in triplicate. A further
48 h later, 0.1 mg of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltretrazolium bromide (MTT) was added to each
well. Cells were incubated at 37°C for 1 h, media removed
and formazan precipitates resuspended in 200 μl DMSO.
Absorbance at 570 nm, with a reference wavelength of
655 nm, was determined in a Model 680 microplate reader
(BioRad) and reported normalised to the cell control,
which was not transfected or treated with TSA.
Immune response
TZM-bl cells were seeded at 3 × 104 cells per well in a
24-well culture plate and transfected with 500 ng shRNA
expression construct or 1 μg of the double-stranded
RNA polyinosinic:polycytidylic acid (poly(I:C) (Sigma-
Aldrich) as a positive control, in triplicate. Total RNA
was extracted using TriReagent (Sigma-Sldrich) 48 h
post-transfection and subject to DNase treatment, re-
verse transcription and qPCR, as described above.Primers used to amplify interferon-β mRNA (ifnb1)
were: forward TCC AAA TTG CTC TCC TGT TGT
GCT; and, reverse CCA CAG GAG CTT CTG ACA
CTG AAA A. ifnb1:actb expression ratios were normal-
ised to the mean expression ratio of U6-transfected
samples.Virus preparation and propagation
1.2 × 106 HEK293T cells were seeded in a 25 cm2
culture flask and transfected 24 h later, using PolyFect
transfection reagent (Qiagen), with 4 μg of subtype B
molecular clone p81A-4 (HIV-1p81A-4) (NIH AIDS Re-
search & Reference Reagent Program) [29,30]. Media was
replaced 24 h later. A further 24 h later, media was col-
lected, filtered, made up to 20% FCS, aliquoted and stored
at −80°C.
Median tissue culture infectious dose (TCID50) was
determined using the Spearman-Karber method [41,42].
TZM-bl and SupT1 cells were seeded at 1 × 104 cells
per well in a 96-well culture plate and infected with vari-
ous dilutions of virus, in triplicate, 24 h later. For TZM-
bl cells, infections were carried out in the presence of
15 μg/ml DEAE-D. Cells were washed with PBS 24 h
post-infection, referred to as day 0. For TZM-bl cells,
luciferase activities were determined in cell lysates 48 h
post-infection using the Bright-Glo Luciferase Assay Sys-
tem (Promega). Samples were considered luciferase posi-
tive if the luminescence signal was greater than that of
the mean of the no virus samples plus two standard
deviations. SupT1 cells were incubated for 7 days post-
washing and both day 0 and day 7 culture supernatant
samples were analysed for the HIV-1 antigen p24 by
ELISA using the HIV antigen mAb Kit (Murex Biotech).
Samples were classed as positive if the A450 was greater
than the absorbance of the kit’s negative control + 0.50.HIV-1 replication in TZM-bl reporter cells
TZM-bl cells were seeded at 5 × 104 cells per well in a
24-well culture plate and transfected 24 h later with 500 ng
shRNA expression constructs and 10 ng pCI-eGFP, in trip-
licate. Cells were infected with either FV5 or HIV-1p81A-4
at a TCID50 of 1000/ml 24 h later in the presence of
15 μg/ml DEAE-D. Cells were washed with PBS 24 h post-
infection. Forty-eight hours post-infection, 100 μl of
culture supernatant was removed and stored at −80°C for
subsequent analysis of p24 levels using the HIV antigen
mAb Kit (Murex Biotech). Another 100 μl of culture
supernatant was used to infect additional TZM-bl cells,
seeded at 5 x 104 cells per well in a 24-well culture plate
the preceeding day, in the presence of 15 μg/ml DEAE-D.
Tat-induced luciferase activities were determined in
cell lysates 48 h post-infections using the Bright-Glo
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malised to the U6 mock.
Generation of shRNA-expressing SupT1 cell lines
shRNA expression cassettes were excised from pTZ
plasmids by digestion with EcoRI and AccI and cloned
into the EcoRI and ClaI sites of second generation lenti-
vector pLVTH (Addgene plasmid 12262, deposited by
D. Trono) [43], which encodes a GFP reporter. Lenti-
viruses were generated from the shRNA-expressing len-
tivectors by transfecting 3.6 × 106 HEK293T cells in a 60
cm2 culture dish 24 h later with 5 μg shRNA-expressing
lentivector, 3.8 μg psPAX2 and 2.5 μg pMD2.G
(Addgene plasmids 12260 and 12259, respectively, both
deposited by D. Trono). Culture media collected 24 and
48 h post-transfection was pooled, filtered and stored at
−80°C. Lentiviruses were titred based on non-linear re-
gression of the number of GFP+ SupT1 cells following
transduction with various dilutions of lentivirus. This
was determined using a FACSCalibur flow cytometer
(BD Biosciences) to acquire 5 × 103 events per sample
with analysis by FlowJo 9.1 (Tree Star). SupT1 cells were
gated based on forward and side scatter characteristics
and GFP+ cells determined from that subset by compari-
son of transduced with untransduced cells.
SupT1 cells were seeded at 3 × 105 cells per 75 cm2
culture flask and incubated with lentivirus at a MOI of
0.15. Cells were cultured for 5 days prior to harvest and
fluorescence activated cell sorting (FACS) on a FACSCa-
libur. Sorted GFP+ cells were concentrated by centrifu-
gation and cultured in DMEM with 20% FCS, 100 U/ml
penicillin, 100 μg.ml streptomycin, 50 μg/ml tetracycline,
100 μg/ml ampicillin, 170 μg/ml chloramphenicol,
50 μg/ml kanamycin and 100 μg/ml ciprofloxacin for
1 week. Sorted cell lines were cultured for a further week
without antibiotics and stocks made. The proportion of
GFP+ SupT1 cells in each cell line was determined by
flow cytometry and FlowJo analysis (Tree Star) based on
the acquisition of 5 × 103 events immediately prior to
sorting (pre-sort) and freezing (post-sort). Thawed
SupT1 cell lines were cultured for 5 days prior to seed-
ing in all subsequent experiments.
HIV-1p81A-4 replication in SupT1 cell lines
SupT1 cell lines with shRNA expression were seeded
at 2 × 104 cells per well in a round-bottomed 96-well
culture plate and immediately infected with HIV-
1p81A-4 at a TCID50 of 50/ml in duplicate. Mock
SupT1 cells with the U6 promoter but no shRNA ex-
pression were cultured both with and without infec-
tion as controls. Twenty-four hours post-infection,
cells were washed with PBS, resuspended in 350 μl
media and pelleted prior to removal of 150 μl media
as day 0 samples. Cells were resuspended withreplacement of the media removed. Cells were pel-
leted and another 150 μl media sample removed
seventy-two hours post-infection (day 2). Samples were
removed in the same fashion on days 4, 7, 10, 14 and 17.
All samples were stored at −80°C prior to analysis of p24
content by ELISA (Murex Biotech). Dilutions of the kit
positive control were used to generate a standard curve of
p24 levels from which absolute levels of p24 in the experi-
mental samples were determined.
Nuclear run-on analysis of htatsf1 transcription
SupT1 cell lines expressing either shhtatsf1-a or shLTR-
U5 were cultured for periods equivalent to days 0 and
20 of the HIV-1p81A-4 replication assay before harvesting
of cell nuclei, in triplicate. Nuclear run-on was per-
formed as previously described [44], with modification
to use biotin-tagged transcripts [45]. Biotinylated RNA
was isolated using Dynabeads MyOne Streptavidin C1
beads (Invitrogen), prior to reverse transcription and
qPCR. htatsf1:actb transcription ratios were normalised
to the mean expression ratio of day 0 samples.
Proliferation of SupT1 cell lines
SupT1 cell lines were analysed by flow cytometry after
culture for periods equivalent to days 0 and 20 of the
HIV-1p81A-4 replication assay (see below). The propor-
tion of GFP+ SupT1 cells in each population was deter-
mined following acquisition of 5 × 103 events on a
FACSCalibur (BD Biosciences) and analysis using FlowJo
9.1 (Tree Star). SupT1 cell lines with shRNA expression
were also seeded at 5 × 104 cells per well in a 12-well
plate in quadruplicate. After 20 days culture, cellular
DNA was extracted and quantified by NanoDrop
(Thermo Fisher Scientific), in duplicate.
Statistics
Data are expressed as the mean ± the standard error of the
mean (SEM). Statistical difference was considered signifi-
cant (*) when p <0.05. Data were analysed using non-linear
regression, unpaired t-test, one-way ANOVA, followed by
Dunnett’s multiple comparison post-tests, and two-way
ANOVA, followed by Bonferroni post-tests, where appro-
priate, using Prism 4.0c (GraphPad Software).
Additional files
Additional file 1: Tat-SF1-targeting shRNAs. Schematic of predicted
structures of shRNAs targeting Tat-SF1 mRNA (htatsf1). G:U wobble base-
pairs, through the introduction of mismatches in the anti-guide strand,
are indicated by black triangles.
Additional file 2: shRNA expression does not alter cell viability.
TZM-bl cells were treated with MTT 48 h post-transfection with shRNA
expression cassettes. Trichostatin-A (TSA) was used as a positive control
for reduced cell viability. Mitochondrial dehydrogenase activity is
reported normalised to the cell control that was untransfected and
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one-way ANOVA with Dunnett post-tests relative to mock construct, U6.
Additional file 3: Generation of shRNA-expressing SupT1 cell lines.
S3A. Dual luciferase activities were assessed in HEK293T cell lysates 48 h
post-transfection with lentivector shRNA expression cassettes and
cognate psiCheck reporter constructs, in triplicate. Target Renilla luciferase
levels are given relative to firefly luciferase and normalised to the U6
mock construct for each psiCheck reporter. Data are expressed as the
mean ± SEM. *, p <0.05, two-way ANOVA with Bonferroni post-tests. S6B.
Representative flow cytometry plots of the SupT1 cell sorting strategy.
SupT1 cells were transduced with lentivirus carrying shRNA expression
constructs and a GFP reporter at a MOI of 0.15. These populations were
sorted to generate a population with >90% GFP expression for use in all
subsequent experiments. S6C. Proportion of GFP+ SupT1 cells in each
population pre- and post-sort based on acquisition of 5 × 103 events by
flow cytometry.
Additional file 4: Time course of shpsip1-a guide strand expression
in SupT1 cells. Total SupT1 RNA was subject to small RNA PAGE and
Northern blot to assess shpsip1-a guide strand expression relative to 5S
rRNAs. Samples were isolated at time points equivalent to days 0 and 20
of the HIV-1p81A-4 replication assay.
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